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Background. Prolonged antihypertensive therapy might be less
effective in reversing the left ventricular hypertrophy (LVH) in
uremics bearing the deleted (DD) allele of the angiotensin
converting enzyme (ACE) gene than in patients with the inserted
(II) allele or in those heterozygous (ID) for the gene.
Methods. Thirteen DD and 17 II1ID hemodialyzed uremics
were followed-up with yearly echocardiography and 24-hour
blood pressure (BP) monitoring over five years while on an
antihypertensive therapy that included ACE inhibitors as first line
drugs.
Results. In the II1ID group there were significant decreases of
the left ventricular mass index (LVMi) and of both systolic and
diastolic BPs. These changes were less pronounced in the DD
group, but the difference was not statistically significant given the
wide overlap between the two groups. Further analysis of the data
revealed that the only factor associated to a decreased LVMi was
the decrease of the systolic BP irrespective of the ACE gene
genotype of each individual patient.
Conclusions. The ACE-gene genotype does not necessarily
predict the extent to which LVMi will be lowered by ACE-
inhibitors therapy. The LVH of hypertensive uremics is amenable
by long-term antihypertensive therapy provided that it results in
significantly decreased systolic blood pressure.
Left ventricular hypertrophy (LVH), which frequently
occurs in chronic uremia [1], can be reversed by prolonged
treatment with antihypertensive drugs [2–4]. There are
differences, however, in the extent to which this therapeutic
regimen reduces the left ventricular mass (LVM), which
most likely are due to the many biological and environmen-
tal factors known to have an influence on the normal and
pathologic growth of the left ventricle (LV) [1, 5].
One such factor could be the genetic background of each
individual patient. In the last few years several studies have
reported on an association between the deletion of a 287
base-pair (bp) repetitive DNA domain in the intron 16 of
the gene encoding for the angiotensin converting enzyme
(ACE) [6] and a series of cardiac abnormalities including
the LVH [7]. A possibility therefore exists that the LVH of
the uremic patients, who bear the shorter or deleted (DD)
gene, is less likely to be amenable to the therapy compared
to the LVH of subjects with the longer or inserted (II) gene
or of those with a heterozygous (ID) genotype.
The purpose of this study was to examine the possible
role of the ACE-gene polymorphism genotype in determin-
ing the pattern of regression of LVH in a group of
hypertensive dialyzed uremics undergoing a long-term an-
tihypertensive therapy, which included ACE-inhibitors as
the first line antihypertensive drug.
To settle this point, we determined the genotype of the
ACE gene in a series of uremic patients who had been
followed-up by yearly echocardiography and 24-hour blood
pressure measurements during a period of five years. This
cohort was on an antihypertensive treatment prescribed in
the attempt both to lower their blood pressure and to
induce a regression of their underlying LVH [2].
METHODS
Patient selection
Patients entering in this analysis were selected from
among those who were already treated or were consecu-
tively admitted for regular replacement therapy at the
36-bed dialysis center of our Division of Nephrology since
early 1992. Subjects were included if they had been on renal
replacement therapy for at least six months, had a diagnosis
of LVH made by state-of-the-art echocardiography, were
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diagnosed to be hypertensive according to a standardized
arbitrary criterion [4], had measurements of 24-hour BP
made by portable monitors, and echocardiographic assess-
ment of the LVM made at least once a year over a period
of five years while under continuous antihypertensive ther-
apy.
Concurrent illness (such as malignancy or chronic in-
flammatory diseases) forecasting a reduced life expectancy,
or well known LVH-inducing causes except for arterial
hypertension (such as diabetes, coronary artery disease,
myocardial infarction, significant valvular regurgitation or
recurrent congestive heart failure), were excluded by stan-
dard history, physical examination, routine laboratory tests
and specific diagnostic studies when needed.
Thirty subjects, all white Caucasians, were finally en-
rolled in the study. Some patients were already participat-
ing in previously reported prospective studies [3], and all of
them were aware of their inclusion in the present analysis.
All subjects were dialyzed three times per week, with the
duration of the treatment (4 to 4.5 hr) and dialyzer surface
area (1.3 to 1.8 m2) prescribed individually according to the
urea-kinetic model criteria [8]. The solute concentrations in
the dialysis bath were: sodium from 139 to 141, potassium
from 2.5 to 3.5, calcium from 2.5 to 3 and bicarbonate 33 to
35 mEq/liter. The intradialytic body weight (body wt)
decrease and dialysate sodium concentration were individ-
ually tailored with the aid of controlled ultrafiltration and
sodium-delivering computer-assisted dialysis machines.
The ideal “dry” body wt was assessed on a clinical basis
[9], and for dubious cases by X-ray of the chest and
extemporary echocardiography. If the prescribed “dry”
post-dialysis body wt was not reached or the usual interdia-
lytic body wt gain was occasionally exceeded, the dialysis
sessions were prolonged or additional sessions per week
were allowed until the planned dry body wt was achieved.
The subjects were placed on a diet with protein content
from 1.1 to 1.2 g/day, with unrestricted salt intake. If,
however, the patients experienced excessive thirst or excess
interdialysis body wt gain, a salt restricted diet was pre-
scribed until the above symptoms had subsided.
All patients were treated with intermittent courses of
subcutaneous rHu-EPO given at a dosage adequate enough
to maintain their Hb levels up to 10 g/dl. They also took
oral or i.v. calcitriol and calcium carbonate or acetate
tablets.
The sera of all patients were routinely tested, with serial
determinations of pre-dialysis Hb, urea, and intact circulat-
ing parathormone (iPTH) made at least monthly on a long
interdialysis interval.
Antihypertensive therapy
All patients were started on antihypertensive therapy
after a diagnosis of arterial hypertension [2, 4] was made on
the basis of 24-hour continuous ambulatory BP monitoring
(CABPM) and a diagnosis of LVH [LVM index . 120 g/m2
body surface area (BSA)] made on echocardiography.
Once the diagnosis of arterial hypertension was made,
subjects were started on a treatment with the ACE-inhibi-
tor lisinopril, from 2.5 to 5 mg daily, to be taken in the late
afternoon. The goal of antihypertensive therapy was to
obtain an average of the pre- and post-dialysis supine
diastolic BP, as measured by routine sphygmomanometry,
within 75 to 85 mm Hg and systolic BP below 140 mm Hg.
The therapy was titrated every month on the basis of the
average BP of the month. If the goal was not achieved, the
calcium channel blocker nifedipine, at a daily dose of 20 mg
slow-release tablets, was added. By late 1993 this drug was
substituted with the same molecule given at a 30 mg daily
dose as GITS (extended release) tablets. If the goal was still
not met, the beta-blocker atenolol was added at an oral
maximal dose of up to 50 mg a day. Further increments of
the antihypertensive drugs dosages were only attempted
with lisinopril at a maximal dose of up to 20 mg a day.
The CABPM was carried out starting in the morning of
a mid-week interdialysis day by a portable monitor
(Spacelabs 90207). Subjects were monitored on a day
chosen for their usual weekly activity. The ambulatory BP
recordings were obtained every 30 minutes during conven-
tional waking hours (from 8 a.m. to 8 p.m.) and every 60
minutes during evening and sleeping hours. After comple-
tion of the recording, data were electronically transferred
by software to an IBM compatible computer and processed
for deletion of errors. The mean 6 SDs were calculated by
using a PC interface software for IBM. Values for 24-hour
systolic and diastolic ambulatory blood pressures were
averaged and stored on a file to be used for subsequent
statistical analyses. The echocardiography was usually per-
formed within a week before or after the CABPM was
made. The echotracings were collected according to a
widely accepted method [10] and were read in a blinded
fashion [11] by a single experienced observer. The measure-
ments included the end diastolic diameter of the left
ventricle, the interventricular septum thickness and the
thickness of the left ventricular posterior wall. Criteria for
adequacy of collection, reading and reproducibility of our
echocardiographic measurements as well as normal values
for healthy controls in our laboratory have been reported
elsewhere [2, 11]. The LVM was calculated from the above
measurements according to the modified Penn-Cube for-
mula [12].
Genomic typing of ACE insertion/deletion polymorphism
High molecular weight DNA was isolated from fresh or
frozen blood samples by either a modified salting out
protocol [13] or denaturation/precipitation with trimethyl-
ammonium bromide [14]. Approximately 0.1 mg DNA was
amplified by the polymerase chain reaction (PCR) tech-
nique [15]. The PCR products were analyzed on 2%
agarose gel-electrophoresis to detect the deletion/insertion
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polymorphism of the ACE gene. All DNA samples identi-
fied as potentially containing DD genotypes were then
genotyped again by a second independent amplification
with a different primer pair as previously described by
Lindpaintner and colleagues [16].
For the purpose of comparison between the study group
and our dialysis population at large, the genomic typing of
the ACE gene I/D polymorphism was also performed in 87
additional dialyzed subjects currently under treatment at
our center.
Calculation and statistics
The adequacy of dialysis dose delivered was calculated
with the simplified Kt/V formula according to Lowrie [17].
The calculation of the Hardy-Weinberg equilibrium was
made according to the procedure from the Linkage Utility
Programs [18].
Fisher’s exact test was used to compare frequencies of
the ordinal variables between groups. The linear regression
analysis was calculated by the least squares method, while
the multiple linear correlations were made by stepwise
multiple regression analysis. Within patient comparisons
were made by analysis of variance (ANOVA) for repeated
measures. A mixed design analysis of variance (two-way
ANOVA) was done for the between subject factor of
genotype and within subject factor of treatment time. When
the F test was significant, the Student’s t-test was used for
comparison of two groups. Differences for more than two
groups were analyzed by ANOVA. Unless otherwise stated,
the data are presented as mean 6 SEM.
Statistical analyses on the ACE-inhibitor doses were
made by non-parametric tests. Between group comparisons
were made by the Mann-Whitney test and within group
comparisons by the Wilcoxon-test, while the significance of
the changes of the dosages versus time was assessed by
means of the Spearman rank correlation analysis.
Changes of the LVMi for each individual patient were
considered significant if they exceeded a value of 6 10%
compared to the basal measurement [3, 11].
RESULTS
Among the overall group of dialyzed uremics of our
center (N 5 87) tested for ACE gene polymorphism, the
frequencies of the allele were DD 39 (44.8%), ID 38
(43.6%) and II 10 (11.3%), and nearly matched those
predicted by the Hardy-Weinberg equilibrium: 36.7, 39.6
and 10.6, respectively.
The characteristics of the cohort study population are
summarized in Table 1. The distribution of the alleles
among the subjects under study (N 5 30) was DD 43%, ID
43% and II 13%, which almost completely replicated that
observed in the overall uremic group.
Since one purpose of our study was to evaluate the
pattern of regression of LVH according to the ACE-gene
genotype, and since the patient population included too
few subjects with the II genotype for adequate statistical
comparison, the I homozygous genotype and heterozygous
patients were pooled as a single group (N 5 17) after
having verified that no major differences existed between
the II and ID subgroups as far as basal levels of systolic
(153 6 6 vs. 149 6 4 mm Hg; t 5 0.46, NS) diastolic (89 6
7 vs. 84 6 2 mm Hg; t 5 1.08, NS) blood pressures and
LVMi (204 6 18 vs. 198 6 17 g/m2 BSA; t 5 0.17, NS) were
concerned. Patients were then categorized into two groups:
II1ID (N 5 17) and DD (N 5 13). They did not differ in
terms of the ratio of women to men (7 of 17 vs. 6 of 13),
anagraphic (26 to 75 vs. 25 to 61 years) or dialytic age at
entry (6 to 124 vs. 6 to 112 months).
ANOVA analysis for changes over time for the entire
group as a whole revealed that there were significant
decreases of the LVMi (F 5 8.12; P , 0.0001) by the first
year (183 6 10 g/m2; t 5 3.59; P 5 0.0012), and for both
systolic (F 5 6.98; P , 0.0001) and diastolic (F 5 4.25; P 5
0.0013) monitored blood pressure (AMBP) since the first
(145 6 2 mm Hg; t 5 2.1; P 5 0.044) and the fourth year
(78 6 1 mm Hg; t 5 3.13; P 5 0.0039), respectively. There
were also significant improvements in both hemoglobin
(Hb) levels (to 10 6 0.2 g/dl, F 5 5.75; P 5 0.0001) and
indices of dialysis efficiency (Kt/V 1.22 6 0.02; F 5 8.17;
P , 0.0001). Multiple regression analysis used to assess the
extent of correlation of the changes of all these putative
independent variables with the corresponding changes oc-
curring in the LVMi at the fifth year yielded no statistical
associations, except for when a loose correlation by univar-
iate analysis between the decrease of the LVMi and the
systolic AMBP was found (Fig. 1).
The patients in the DD group were started on lisinopril
therapy at a daily median dose of 5 mg (range 2.5 to 5,
mean 3.84 mg). Some patients, however, were progressively
shifted to higher than initial doses, such that the range of
the drug dosage widened significantly to 20 mg a day after
four years on treatment (Wilcoxon test, P 5 0.016), while
the average dose for the entire group (7.88 mg) also tended
Table 1. Pertinent clinical, echocardiographic and demographic data
for a group of uremic patients at entry into this prospective study
Variable Study group
N 30
Gender ratio women to men 12/18
Age years 52 6 3
Dialytic age months 45 6 7
24-Hr systolic blood pressure mm Hg 150 6 2
24-Hr diastolic blood pressure mm Hg 84 6 1
Interventricular septum thickness mm 14.0 6 0.8
Left ventricular posterior wall thickness mm 11.3 6 0.4
Left ventricular end diastolic diameter mm 53.5 6 1.5
Calculated left ventricular mass index g/m2 BSA 203 6 10
Hemoglobin g/dl 9.0 6 0.2
Intact parathyroid hormone pg/ml 259 6 44
Kt/V 1.04 6 0.03
ACE-gene genotype number of patients 13 DD, 13 ID, 4 II
Values are given as mean 6 SEM. BSA is body surface area.
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to increase significantly over time (Spearman, r 5 0.928;
P 5 0.017). The starting median dose of 5 mg (range 2.5 to
10) of lisinopril given to the II1ID patients did not differ
from that given to DD subjects (Mann-Whitney u 5 94.5;
P 5 0.51) and remained almost steady over the entire
treatment period (Spearman, P 5 0.18).
Seven out of 13 patients (54%) of the DD group took
nifedipine, as did a similar proportion (9 of 17) of the
II1ID patients. The number of patients taking atenolol was
also similar in the two groups (3 of 13 and 4 of 17).
Figure 2 shows data for LVMi and AMBPs taken every
twelve months for both the DD and the II1ID groups.
At the beginning of the observation period there were no
differences between groups with respect to their LVMi or
AMBP levels. With antihypertensive therapy, the LVMi
decreased significantly in the II1ID group (F 5 6.035; P 5
0.0001; ANOVA) from the first year on treatment (t 5 3.1;
P 5 0.007) onward, further diminished by the third year,
then remained unvaried thereafter. Both systolic and dia-
stolic AMBP for the II1ID group decreased significantly
(F 5 6.5; P 5 0.0001 and F 5 3.67; P 5 0.005; by ANOVA)
starting by the second (t 5 2.71; P 5 0.016) and the fourth
year (t 5 2.65; P 5 0.017), respectively. All these changes
in LVMi and AMBPs were seen in the DD group too, but
these trends never reached statistical significance.
When two-way ANOVA was done for between subject
factor of the genotype and within subject factor of treat-
ment time, no statistically significant differences between
groups could be seen as far as changes of LVMi, systolic
and diastolic AMBPs were concerned. Analysis of the
individual percent changes for the LVMi according to the
genotype is illustrated in Figure 3. After five years on
antihypertensive therapy, the LVMi decreased significantly
in 11 out 17 patients of the II1ID group, while it remained
unvaried in four and even rose in the remaining two. Eight
patients in the DD group experienced a decrease in their
LVMi, three had unvaried LVMi and two had an increase.
Overall, the extent of the LVMi decrease in the DD group
was 111 6 6% (range 231 to 130%), lower than that
observed in II1ID individuals (123 6 6%, range 262 to
122%); this difference was not significant (t 5 1.45; P 5
0.16), however.
When patients were categorized according to the extent
of D% in LVMi (LVMi unvaried or raised above 10% vs.
LVMi decreased below 10% or more) the two resulting
groups were indistinguishable from each other for a series
of variables except for the average yearly decrease of
systolic blood presure, which was found to be significantly
greater for those individuals with significantly decreased
LVMi (Table 2).
DISCUSSION
The prevalence of DD homozygous individuals among
113 out of a total of 130 patients currently being treated at
our dialysis center was 42%. These findings do not fit well
with those recently reported by Schmidt and colleagues for
a group of 106 hemodialyzed uremics in whom the preva-
lence of DD was estimated to be about 26% [19]. Mistyping
of the I allele leading to a false attribution of a double D
allele to already heterozygous subjects might have falsely
amplified the prevalence of the D allele within our uremic
population [20]. The procedure we used to correctly iden-
tify the D allele, however, made mistyping of the I for the
D allele very unlikely [16]. An alternative explanation could
lie in the differences in terms of rates and causes of
mortality between our patient population and that studied
Fig. 1. Changes of left ventricular mass indices
plotted against corresponding changes in
systolic blood pressures occurring after five
years on continuous antihypertensive therapy
in 30 chronically hemodialyzed uremics (r 5
0.37; P 5 0.044).
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by Schmidt et al. If, in fact, one assumes that DD genotype-
patients carry a significantly higher mortality for cardiovas-
cular causes than do patients with other genotypes [21], the
pool of DD patients within a dialysis population would
eventually disappear over the time spent on dialysis [21,
22]. Actuarial survival time of patients with LVH in our
center reaches 58% after five years (unpublished data).
Data on the death rates of patients in the study of Schmidt
et al, however, are not available, thus making any compar-
ison between ours and the above findings merely specula-
tive.
The LVM is a multifaceted phenotype on which the
influences of many inherited, racial, anthropological as well
as acquired environmental factors converge [5]. LVH is an
even more complex phenotypic aggregate than is LVM,
since it also reflects the effects on the heart of several
pathologic factors including endocrine overflows, raised
BP, large body size and mass, deviant dietary and addictive
habits, etc. [5], whose duration, severity and influence on
LV growth are not known.
Weighing the influence of each individual factor, among
the congeries of all those possibly affecting LV growth, may
therefore not be readily feasible. Thus, it is not surprising
that the results of population-based cross sectional studies,
aimed at ascertaining an association of the ACE-gene
genotype with the LVH, have led to contrasting conclusions
[7, 23, 24].
The LVH phenotype of chronic uremia might be even
more complex than it is in the general pathologic non-
uremic population, owing to additional factors specific to
uremic status that may affect the LVM [1]. Hence, it is not
surprising that no associations were found between preva-
lence of LVH and ACE genotypes in a recently published
cross-sectional study of chronic uremic patients [19].
In keeping with the above, most of our subjects suffering
from LVH did not have a DD genotype.
Inconsistent results arising from the above cross-sec-
tional studies, however, do not allow inferring the lack of a
Fig. 2. Values (mean 6 SEM) of 24-hour monitored systolic (S) and
diastolic (D) blood presures (BP) and left ventricular mass indices
(LVMi) for groups of hypertensive hemodialyzed uremics bearing the DD
(F; N 5 13) or II/ID (E; N 5 17) ACE-gene genotype while on continuous
antihypertensive therapy that included ACE inhibitors. Asterisks indicate
the time at which a significant difference was detectable with respect to the
basal value.
Fig. 3. Percent changes for the left ventricular mass indices after five
years on a continuous antihypertensive therapy, which included ACE
inhibitors, for 30 hemodialyzed uremics bearing different ACE-gene
genotype (F DD; ID; E II). The “F” value for possible differences
among groups, by ANOVA, is indicated.
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role for the ACE-genotype in modulating the effects that
the renin-angiotensin system might have in driving the
pathologic LV growth. Circulating angiotensin is believed
to induce vasoconstriction with fine tuning of the hemody-
namics within the vascular tree, while tissular angiotensin is
thought to be a key factor in a process whereby the
hemodynamic overload is transduced into a paracrine
signal for myocardial cells to grow [25–27].
Some years ago, studies appeared demonstrating that
individuals homozygous for the D allele had the highest
values for serum [28] and cardiac tissue [29] ACE activity
compared to those with the inserted gene, with the het-
erozygous ID individuals expressing intermediate ACE
levels. Thus, elevated ACE levels, through accelerated
conversion of angiotensin I, may lead to raised angiotensin
II levels both within the heart and throughout the systemic
circulation [29, 30]. In the case of arterial hypertension one
might therefore hypothesize that the resulting hemody-
namic load would be transduced more in those subjects
endowed with the DD genotype. To prove the above,
however, would require the availability of a prospective
cohort of subjects with different ACE-gene genotypes, who
would be given a hemodynamic load such that different
slopes between the ensuing arterial hypertension and the
degree of the conveyed LV growth could be constructed
[24].
Such a study is, for all practical purposes, unfeasible. We
therefore conceived the present analysis by reasoning that,
if the above hypothesis is straightforward, then treatment
with ACE inhibitors, which weaken the ACE activity,
would result in a pattern of regression of LVM over the
blood pressure that would differ from one subject to the
other according to his or her ACE-gene genotype. The
availability of pertinent data for a cohort of thirty uremics
undergoing antihypertensive therapy with ACE inhibitors
and prospectively followed-up for five years offered us this
opportunity.
The overall findings of the present study confirm and
extend those of former reports by us on the effectiveness of
long-term antihypertensive therapy in improving or even
reversing the LVH of hemodialyzed uremic patients [2, 3].
These results are also consistent with those already re-
ported for non-uremic hypertensive patients undergoing
aggressive antihypertensive treatment over a period of time
similar to that of the patients in the present study [31].
Thus, these newly collected data provide stronger evidence
of the prominent role of arterial hypertension in causing
LVH in chronic uremics [2, 3]. In the present study,
however, not all the patients benefited from prolonged
antihypertensive therapy to the same extent, the ameliorat-
ing cardiac effects of this therapy being seemingly prevalent
in those bearing at least one I allele in the intron 16 of the
ACE gene. In our II1ID group, in fact, the average LVM
was found to be reduced from the first year. These changes
in LVM anticipated those occurring in systolic AMBP,
which became significant from the second year onwards,
and occurred even earlier than those of diastolic AMBP,
which was found to be decreased only from the fourth year.
Thus, these findings corroborate previous observations in
both uremic and nonuremic hypertensive and normoten-
sive humans and rats [4, 32–34] that the ACE inhibitors are
able to induce a decrease of LVM through mechanisms
that are independent of blood pressure. Contrary to the
significant tendencies of both LVM and BP towards reduc-
tion in our II1ID group, the average values for these
parameters in the DD group, although moving in a similar
trend, did not change significantly. This occurred despite
the fact that the patients in the DD subgroup had under-
gone an antihypertensive treatment with nifedipine and
atenolol of a comparable strength and even stronger ACE
inhibitor therapy compared to the II1ID subgroup of
patients. Thus, it seems from the above data that the
homozygous D subjects might be poorly responsive to the
hypotensive therapy and might also have a resistance
towards both the hemodynamic and the non-hemodynamic
effects that the ACE inhibitors are potentially able to exert
on the LVM and on BP.
These differences in blood pressure and LVM trends in
Table 2. Clinical, demographic and laboratory data for patients with decreased left ventricle mass index (LVMi) compared to those of patients
with raised or unchanged LVMi
Variable D LVMi $ 210% D LVMi # 29% Test Probability
N 19 11
Age years 50 6 3 54 6 4 t-test NS
Dialytic age months 44 6 8 46 6 13 t-test NS
SBP at entry mm Hg 154 6 3 144 6 4 t-test NS
DBP at entry mm Hg 85 6 2 82 6 3 t-test NS
DSBP (average yearly) mm Hg 25 6 1 21 6 1 t-test 5 0.025
D DBP (average yearly) mm Hg 22 6 1 21 6 1 t-test NS
D Kt/V 0.18 6 0.04 0.15 6 0.06 t-test NS
D Hb g/dl 1.47 6 0.42 0.24 6 0.33 t-test NS
ACEi (average yearly dose per day) mg 5 (2.5–15) 5 (2.5–12.5) Mann-Whitney NS
Women/men ratio 14/5 4/7 Fisher’s exact test NS
Genotype (DD, ID, II) 8, 9, 2 5, 4, 2 Fisher’s exact test NS
Abbreviations are: S, systolic, and D, diastolic; BP, blood pressure; Hb, concentration of hemoglobin; ACEi, angiotensin converting enzyme inhibitor.
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the two groups, however, are doubtful, since they failed to
reach statistical significance when entering a mixed design
analysis of variance for possible differences for the between
group factor of the genotype over the treatment time. This
fact probably occurred because the behavior of some
individuals diverged with respect to the average behavior of
the group to which they belonged, since some of them
overlapped with those of the contrasted group.
Admittedly, the small sample size is the primary limita-
tion of this study and raises concerns about these negative
findings. Conceivably, a significant difference between ge-
notype groups might have been observed if a sufficiently
large number of DD subjects had been enrolled for analy-
sis. This intrinsic weakness, however, should have been
balanced by the extended duration of our study; in fact,
were the ACE genotype a factor strong enough to influence
the slope of regression of LVM and BP with time, it would
have produced more clear-cut dissociations between trends
of the two subgroups over the broad time frame during
which the observations were made.
The above findings would appear disappointing when
viewed from the perspective of the actractive hypothesis
that prompted this analysis. They do, nonetheless, fit well
with a recent study where the ACE-gene genotype ac-
counted for only a lower than 5% of the total variance of
the LVM in a group of essential hypertensives [35].
Indeed, there are several reasons why our findings might
not reflect falsely negative results. For the ACE-gene to be
strong enough to entirely convey its message according to
its polymorphism would require that no other contending
factors have major roles in activating the renin-angiotensin-
cascade. This is not the case, however. In white Caucasians
the ACE genotype accounts for only half of the total
variance of the serum ACE concentrations [28], while in
black Americans of African descent the ACE phenotype is
completely unrelated to the I and D alleles [36]. If there are
racial differences in the transcriptional regulation of the
ACE phenotype, therefore, it is possible that such differ-
ences also exist within subjects of the same racial group.
Indeed, in a more recent report on Caucasians, the associ-
ation between I and D alleles with ACE activity was found
to be even lower than previously reported [37], thus
alluding to the existence of other powerful alleles possibly
controlling the ACE phenotype [38]. Furthermore, there
are factors other than ACE activity that determine the final
levels at which angiotensin II is produced. These include
the availability of angiotensinogen, the cleavage activity of
the renin enzyme, not to mention the ACE-independent
angiotensin II formation through chymase and chymase-
like angiotensin II tissue-forming enzymes [39]. The ACE-
gene polymorphism genotype, therefore, should not to be
the dominant factor whereby angiotensin II is delivered to
tissues. To this end, illustrative arguments have been
provided by a study of Harrapp and colleagues [37] in
which somewhat higher plasma levels of angiotensin II
were found in the II as compared to DD genotype-bearing
subjects.
In our study the only factor found to be associated with
a decreased LVM was a lowered systolic blood pressure.
This finding is reminiscent of the several studies appearing
over the last few years that concordantly report systolic
blood pressure as the most powerful clinical correlate to
the LVH of dialyzed uremics [40, 41]. Not all our patients
had a significant decrease of their LVM despite having an
ACE inhibitor therapy at least as strong as those who had
their LVM lowered. Individual differences in blood pres-
sure and myocardial responses to ACE inhibitor therapy
might possibly explain the unsatisfactory BP and LVM
decrease in these patients. A well accepted notion is that
plasma volume expansion does confer a resistance toward
the hypotensive effects of ACE inhibitors. Subtle expan-
sions of the extracellular fluid volumes, owing to the
extreme difficulty entailed in finely assessing the ideal
effective circulating volume in these patients [42], might
therefore have been a factor of resistance to the therapy in
our subjects. We doubt, however, that major expansions of
circulating blood volume went unnoticed over the very long
period of time our subjects remained in the study.
Resistance to the hypotensive effects of ACE inhibitors
might also be conferred by some still uncompletely known
individual and genetic factors [43], as well as by different
polymorphisms of the gene regulating the expression of the
type 1 angiotensin II receptor [44]. Raising the dosages of
the ACE inhibitors might overcome the apparent resis-
tance to these drugs [43]. A more powerful antihyperten-
sive therapy with ACE inhibitors, or a combination of ACE
inhibitors with drugs blocking the angiotensin II receptor 1
[45], might likely very well have performed better than the
therapy we adopted. This type of treatment should be
tested in the near future, and to this end close monitoring
of chronic uremics by echocardiography would help to
identify those patients whose LVH is seemingly unrespon-
sive to the ACE inhibitor therapy, thus providing them with
further therapeutic opportunity for cure of their cardiac
disease.
In conclusion, this paper has reiterated the possibility to
successfully treat the LVH of hypertensive uremics by
reversing it or by slowing its progression. Patients endowed
with the II or ID genotype of the ACE gene seem to be
more amenable to an antihypertensive therapy with ACE
inhibitors as first-line drugs. The decisive factor leading to
a lowered LVM, however, is a consistent decrease of the
systolic blood pressure. Aggressive treatment of systolic
hypertension, in patients seemingly resistent to ACE inhib-
itors, will probably add further benefits in curing the LVH
of these patients.
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APPENDIX
Abbreviations used in this article are: ACE, angiotensin converting
enzyme; ACEi, angiotensin converting enzyme inhibition; AMBP, ambu-
latory monitored blood pressure; BP, blood pressure; BSA, body surface
area; CABPM, continuous ambulatory blood pressure monitoring; DBP,
diastolic BP; DD, deleted gene; Hb, hemoglobin; ID heterozygous geno-
type; II, inserted gene; iPTH, intact parathyroid hormone; Kt/V, dialysis
efficiency; LV, left ventricle; LVH, left ventricle hypertrophy; LVM, left
ventricular mass; LVMI, left ventricle mass index; PCR, polymerase chain
reaction; rHU-EPO, recombinant human erythropoietin; SBP, systolic
blood pressure.
REFERENCES
1. LONDON GM, FABIANI F: Left ventricular dysfunction in end-stage
renal disease. Echocardiographic insights, in Cardiac Dysfunction in
Chronic Uremia, edited by PARFREY PS, HARNETT JD, Basel, Kluwer
Academic Publishers, 1992, pp 117–137
2. CANNELLA G, PAOLETTI E, DELFINO R, PELOSO GC, MOLINARI S,
TRAVERSO GB: Regression of left ventricular hypertrophy in hyper-
tensive dialyzed uremic patients on long-term antihypertensive ther-
apy. Kidney Int 44:881–886, 1993
3. CANNELLA G, PAOLETTI E: Myocardial hypertrophy in chronic renal
failure: A multifactorial, reversible alteration. Contrib Nephrol 119:
135–140, 1996
4. CANNELLA G, PAOLETTI E, DELFINO R, PELOSO GC, ROLLA D,
MOLINARI S: Prolonged therapy with ACE-inhibitors induces a regres-
sion of left ventricular hypertrophy of dialyzed uremics independently
from hypotensive effects. Am J Kidney Dis 30:659–664, 1997
5. MESSERLI FH: Pathophysiology of left ventricular hypertrophy, in Left
Ventricular Hypertrophy and Its Regression, edited by CRUICKSHANK
KJM, MESSERLI FH, London, Science Press, 1992, pp 13–20
6. SOUBRIER F, ALHENC-GELAS F, HUBERT C, ALLEGRINI J, JOHN M,
TREGEAR G, CORVOL P: Two putative active centers in human
angiotensin I-converting enzyme revealed by molecular cloning. Proc
Natl Acad Sci USA 85:9386–9390, 1988
7. SCHUNKERT H, HENSE HW, HOLMER SR, STENDER M, PERZ S, KEIL
U, LORELL BH, RIEGGER GAJ: Association between a deletion
polymorphism of the angiotensin-converting-enzyme gene and left
ventricular hypertrophy. N Engl J Med 330:1634–1638, 1994
8. SARGENT JA, GOTCH FA: Mathematic modeling of dialysis therapy.
Kidney Int 18(Suppl 10):S2–S10, 1980
9. HEYKA RJ, PAGANINI EP: Blood pressure control in chronic dialysis
patients, in Replacement of Renal Function by Dialysis (3rd ed), edited
by MAHER JF, Basel, Kluwer Academic Publishers, 1989, pp 772–787
10. MCROURKE RA, HANRATH P, HENRY WN, HUGENHOLTZ PG, PISA Z,
ROELANDT J, TANAKA M: Report of the Joint International Society
and Federation of Cardiology/World Health Organization task force:
Recommendations for standardization of measurements from M-
mode echocardiograms. Circulation 69:854A–857A, 1984
11. CANNELLA G, LACANNA G, SANDRINI M, GAGGIOTTI M, NORDIO G,
MOVILLI E, MOMBELLONI S, VISIOLI O, MAIORCA R: Reversal of left
ventricular hypertrophy following recombinant human erythropoietin
treatment of anaemic dialysed uraemic patients. Nephrol Dial Trans-
plant 6:31–37, 1991
12. DEVEREUX RB, ALONSO DR, LUTAS EM, GOTTLIEB GJ, CAMPO E,
SACHS I, REICHEK N: Echocardiographic assessment of left ventricular
hypertrophy: Comparison to necropsy findings. Am J Cardiol 57:450–
458, 1986
13. OLERUP O, ZETTERQUIST H: HLA-DR typing by PCR amplification
with sequence-specific primers (PCR-SSP) in 2 hours: An alternative
to serological DR typing in clinical practice including donor-recipient
matching in cadaveric transplantation. Tissue Antigens 39:225–235,
1992
14. GUSTINCICH S, MAFFIOLETTI G, DEL SAL G, SCHNEIDER C, CARNINCI
P: A fast method for high quality genomic DNA extraction from whole
human blood. Bio Techniques 1:298–302, 1991
15. SCHMIDT S, STIER E, HARTUNG R, STEIN G, BAHNISH J, WOODROFFE
AJ, CLARKSON R, PONTICELLI C, CAMPISE M, MAYER G, GANTEN D,
RITZ E: No association of converting enzyme insertion/deletion
polymorphism with immunoglobulin A glomerulonephritis. Am J
Kidney Dis 26:727–731, 1995
16. LINDPAINTNER K, PFEFFER MA, KREUTZ R, STAMPFER MJ, GROD-
STEIN F, LAMOTTE F, BURING J, HENNEKENS CH: A prospective
evaluation of an angiotensin-converting enzyme gene polymorphism
and the risk of ischemic heart disease. N Engl J Med 332:706–711, 1995
17. LOWRIE EG, TEEHAN BP: Principles of prescribing dialysis therapy:
Implementing recommendations from the National Cooperative Di-
alysis Study. Kidney Int 23(Suppl 13):S113–S122, 1983
18. OTT J: Analysis of Human Linkage (2nd ed). Baltimore, John Hopkins
University Press, 1991
19. SCHMIDT A, KIENER HP, BARNAS U, ARIAS I, ILLIEVICH A, AUINGER
M, GRANINGER W, KAIDER A, MAYER G: Angiotensin-converting
enzyme polymorphism in patients with terminal renal failure. J Am
Soc Nephrol 7:314–317, 1996
20. FOGARTY DG, MAXWELL AP, DOHERTY CC, HUGHES AE, NEVIN NC:
ACE gene typing. (letter) Lancet 343:851, 1994
21. YOSHIDA H, KON V, ICHIKAWA I: Polymorphisms of the renin-
angiotensin system genes in progressive renal diseases. Kidney Int
50:732–744, 1996
22. OSAKA N, YOSHIDA H, NAKAYAMA M, KUBO H, AIZAWA S, SATO S,
NUMATA M, KAWAGUCHI Y, SAKAI O: ACE DD genotype predisposes
patients on dialysis to cardiac accidents. (abstract) J Am Soc Nephrol
9:1396, 1996
23. LINDPAINTNER K, LEE MA, LARSON MG, SRINIVAS VR, PFEFFER MA,
ORDOVAS JM, SCHAEFER EJ, WILSON AF, WILSON PWF, VASAN RS,
MYERS RH, LEVY D: Absence of association or genetic linkage
between the angiotensin-converting-enzyme gene and left ventricular
mass. N Engl J Med 334:1023–1028, 1996
24. MONTGOMERY H: Should the contribution of ACE gene polymor-
phism to left ventricular hypertrophy be reconsidered? Heart 77:489–
490, 1997
25. LEE MAE, PAUL M, BOHM M, GANTEN D: Effects of angiotensin-
converting enzyme inhibitors on tissue renin-angiotensin systems.
Am J Cardiol 70:12C–19C, 1992
26. DZAU VJ: Tissue renin-angiotensin system in myocardial hypertrophy
and failure. Arch Intern Med 153:937–942, 1993
27. KENT RL, MANN DL, COOPER G: Signals for cardiac muscle hyper-
trophy in hypertension. J Cardiovasc Pharmacol 17:S7–S13, 1991
28. RIGAT B, HUBERT C, ALHENC-GELAS F, CAMBIEN F, CORVOL P,
SOUBRIER F: An insertion/deletion polymorphism in the angiotensin
I-converting enzyme gene accounting for half the variance of serum
enzyme levels. J Clin Invest 86:1343–1346, 1990
29. DANSER JAH, SCHALEKAMP MADH, BAX WA, VAN DEN BRINK AM,
SAXENA PR, RIEGGER GAJ, SCHUNKERT H: Angiotensin-converting
enzyme in the human heart. Effect of the deletion/insertion polymor-
phism. Circulation 92:1387–1388, 1995
30. UEDA S, ELLIOTT HL, MORTON JJ, CONNELL MC: Enhanced pressor
response to angiotensin I in normotensive men with the deletion
genotype (DD) for angiotensin-converting enzyme. Hypertension 25:
1266–1269, 1995
31. FRANZ IW, KETELHUT R, BEHR U, TONNESMANN U: Long-term
studies on regression of left ventricular hypertrophy. J Cardiovasc
Pharmacol 17:S87–S93, 1991
32. LINZ W, SCHOLKENS BA, GANTEN D: Converting enzyme inhibition
specifically prevents the development and induces regression of
cardiac hypertrophy in rats. Clin Exp Hypertension 11:1325–1350, 1989
33. LONDON GM, PANNIER B, GUERIN AP, MARCHAIS SJ, SAFAR ME,
CUCHE JL: Cardiac hypertrophy, aortic compliance, peripheral resis-
tance and wave reflection in end-stage renal disease. Comparative
effects of ACE inhibition and calcium channel blockade. Circulation
90:2786–2796, 1994
34. SUZUKI H, SCHAEFER L, LING H, SCHAEFER RM, DAMMRICH J,
TESCHNER M, HEIDLAND A: Prevention of cardiac hypertrophy in
experimental chronic renal failure by long-term ACE inhibitor admin-
istration: Potential roles of lysosomal proteinases. Am J Nephrol
15:129–136, 1995
35. GHARAVI AG, LIPKOWITZ MS, DIAMOND JA, JHANG JS, PHILLIPS RA:
Deletion polymorphism of the angiotensin-converting enzyme gene is
Cannella et al: ACE-gene polymorphism and LVH in uremia 625
independently associated with left ventricular mass and geometric re-
modeling in systemic hypertension. Am J Cardiol 77:1315–1319, 1996
36. BLOEM LJ, MANATUNGA AK, PRATT JH: Racial difference in the
relationship of an angiotensin I-converting enzyme gene polymor-
phism to serum angiotensin I-converting enzyme activity. Hypertension
27:62–66, 1996
37. HARRAP SB, DAVIDSON HR, CONNOR JM, SOUBRIER F, CORVOL P,
FRASER R, FOY CJW, WATT GCM: The angiotensin I converting
enzyme gene and predisposition to high blood pressure. Hypertension
21:455–460, 1993
38. TIRET L, RIGAT B, VISVIKIS S, BREDA C, CORVOL P, CAMBIEN F,
SOUBRIER F: Evidence from combined segregation and linkage anal-
ysis, that a variant of the angiotensin I-converting enzyme (ACE) gene
controls plasma levels. Am J Hum Genet 51:197–205, 1992
39. NISHIMURA H, HOFFMANN S, BALTATU O, SUGIMURA K, GANTEN D,
URATA H: Angiotensin I converting enzyme and chymase in cardio-
vascular tissues. Kidney Int 49(Suppl 55):S18–S23, 1996
40. HARNETT JD, KENT GM, BARRE PE, TAYLOR R, PARFREY PS: Risk
factors for the development of left ventricular hypertrophy in a
prospectively followed cohort of dialysis patients. J Am Soc Nephrol
4:1486–1490, 1994
41. DE LIMA JJG, ABENSUR H, KRIEGER EM, PILEGGI F: Arterial blood
pressure and left ventricular hypertrophy in haemodialysis patients.
J Hypertens 14:1019–1024, 1996
42. CANNELLA G, PAOLETTI E: Clues for understanding the pathogenesis
of left ventricular hypertrophy in chronic uremia. Int J Artif Organs (in
press)
43. WEIR MR, GRAY JM, PASTER R, SAUNDERS E, FOR THE TRANDOLA-
PRIL MULTICENTER STUDY GROUP: Differing mechanisms of action of
angiotensin-converting enzyme inhibition in black and white hyper-
tensive patients. Hypertension 25:124–130, 1995
44. HINGORANI AD, JIA H, STEVENS PA, HOPPER R, DICKERSON JEC,
BROWN MJ: Renin-angiotensin system gene polymorphisms influence
blood pressure and the response to angiotensin converting enzyme
inhibition. J Hypertens 13:1602–1609, 1995
45. JOHNSTON CI: Angiotensin receptor antagonists: Focus on losartan.
Lancet 346:1403–1407, 1995
Cannella et al: ACE-gene polymorphism and LVH in uremia626
